Home-based, remotely monitored pulmonary rehabilitation increases moderate-to-vigorous physical activity in patients with idiopathic pulmonary fibrosis on antifibrotic therapy
In a randomized controlled trial of 29 patients with IPF, a 12-week home-based, remotely monitored exercise program increased daily moderate-to-vigorous physical activity (MVPA) by 28% in the intervention group, while the control group decreased by 35% (p=0.001 for group*time interaction). The intervention group's improvement of 49±19 min/week was nearly double the minimal clinically important difference for IPF. The program was feasible with 100% completion, 92% adherence, and no adverse events.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Home-based, remotely monitored pulmonary rehabilitation increases moderate-to-vigorous physical activity in patients with idiopathic pulmonary fibrosis on antifibrotic therapy The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Home-based, remotely monitored pulmonary rehabilitation increases moderate-to-vigorous physical activity in patients with idiopathic pulmonary fibrosis on antifibrotic therapy
This conclusion is most relevant to: Patients with idiopathic pulmonary fibrosis on background antifibrotic therapy (n=29 randomized; 15 intervention, 14 control).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Remotely Monitored Home-based Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: Results of a Randomized Controlled Trial. (Archives of physical medicine and rehabilitation, 2026) —
How It Works
The proposed biological pathway:
- ▸Remote monitoring enables personalized exercise prescription and feedback
- ▸Asynchronous monitoring allows safe, home-based training without travel burden
- ▸Increased physical activity leads to improved exercise tolerance and reduced cardiovascular strain (lower BNP)
- ▸Result: Meaningful increase in MVPA and preserved quality of life
Who Might Benefit
Evidence fit by population:
- ▸Patients with idiopathic pulmonary fibrosis on background antifibrotic therapy (n=29 randomized; 15 intervention, 14 control)
Recommended Dose
N/A (exercise program, not a drug dose)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Small sample size (n=29) limits generalizability
- ▸Single-center or regional recruitment may introduce selection bias
- ▸No long-term follow-up beyond 4 weeks post-intervention
- ▸Control group received monitoring only, not a sham exercise program
Frequently Asked Questions
What is the minimal clinically important difference for MVPA in IPF?▼
The abstract states the intervention improvement (49±19 min/week) was almost double the reported minimal clinically important difference for IPF, but the specific MCID value is not given in the abstract.
How was the home-based pulmonary rehabilitation delivered?▼
Patients received a 12-week exercise-focused program with asynchronous remote monitoring using a smartphone-linked accelerometer/HR monitor and a medical-grade fingertip pulse oximeter. The intervention was entirely home-based.
What were the completion and adherence rates?▼
Program completion was 100% and workout adherence for the intervention group was 92%.
Did the intervention improve quality of life?▼
The abstract notes that within-group effects for the intervention included preserved VO2max and quality of life, but does not report a significant improvement over control.
References
- 1.Child CE, Ho LA, Borders E, Gray T, Olson T, Gordon B, Cai HD, Veras-Tobos E, Traylor K, Babu G, Raghu G, Brown MB. “Remotely Monitored Home-based Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: Results of a Randomized Controlled Trial..” Archives of physical medicine and rehabilitation, 2026. PMID: 42532213 DOI: 10.1016/j.apmr.2026.07.019